drugset / Trial / NCT02000596
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase II study that combines Trastuzumab with Pertuzumab to see how it works in women age greater than 60 who have been diagnosed with HER2/neu overexpressed locally advanced and/or metastatic breast carcinoma.
Timeline
- Start
- 2014-01
- Primary completion
- 2015-11
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | 1 mg | Oral |
| Subject | Eribulin | Small molecule | — | — |
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Subject | Pertuzumab | Monoclonal antibody | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |